Drug Search Results
More Filters [+]

Telratolimod

Alternative Names: telratolimod, medi-9197, medi9197, medi 9197, 3m-052
Latest Update: 2024-11-08
Latest Update Note: Clinical Trial Update

Product Description

Telratolimod is a toll-like receptor type 7 and 8 (TLR7/8) agonist with potential immunostimulating and antitumor activities. Upon intratumoral administration, telratolimod binds to and activates TLR7 and 8, thereby stimulating antigen-presenting cells (APCs), including dendritic cells (DCs). Activation of DCs results in the production of proinflammatory cytokines, and the activation of cytotoxic T-lymphocyte (CTL) and B-lymphocyte immune responses. This may cause tumor cell lysis. TLR7 and 8, members of the TLR family, play fundamental roles in the activation of the immune system. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Telratolimod)

Mechanisms of Action: TLR7 Agonist,TLR8 Agonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AstraZeneca
Company Location: CAMBRIDGE X0 CB2 0AA
Company CEO: Pascal Soriot
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Telratolimod

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: HIV Infections|Acquired Immunodeficiency Syndrome|Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HVTN 316

P1

Not yet recruiting

HIV Infections

2027-06-03

A5422

P1

Not yet recruiting

HIV Infections

2026-10-13

HVTN 309

P1

Not yet recruiting

Acquired Immunodeficiency Syndrome|HIV Infections

2025-12-30

HVTN 807

P1

Recruiting

HIV Infections

2025-12-20

Recent News Events